A Global, Randomized, Adaptive Trial to Evaluate the Combination of Tazemetostat with Revlimid plus Rituxan (R2) for Follicular Lymphoma Patients in the Second-Line or Later Treatment Setting
Phase of Trial: Phase III
Latest Information Update: 30 Oct 2019
Price : $35 *
At a glance
- Drugs Lenalidomide (Primary) ; Rituximab (Primary) ; Tazemetostat (Primary)
- Indications Follicular lymphoma
- Focus Registrational; Therapeutic Use
- Sponsors Epizyme
- 30 Oct 2019 According to an Epizyme media release, Epizyme gained alignment with FDA on this single confirmatory trial to support a submission for full approval.Site initiation is underway and the safety run-in portion of the trial is on track to begin in the fourth quarter of 2019.
- 26 Feb 2019 According to an Epizyme media release, the company plans to initiate this study in mid-2019.
- 20 Mar 2018 New trial record